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Impact of Donor Source on Survival
Priya Kumar, Todd E. Defor, Claudio Brunstein, Juliet N. Barker, John E. Wagner,
Daniel J. Weisdorf, Linda J. BurnsWe studied the relative impact of donor source on outcomes following myeloablative hematopoietic stem cell
transplantation (HSCT) for adult patients with acute lymphocytic leukemia (ALL). In this single center study,
138 patients aged 18-61 (median 31) years underwent myeloablative conditioning followed by allogeneic
HSCT. Stem cell source was an HLA matched related donor (MRD) in 90, HLA matched unrelated donor
(URD:M) in 15, HLA mismatched unrelated donor (URD:MM) in 14, and HLA 0-2 (A, B, DRB1) mismatched
umbilical cord blood (UCB) in 19 patients. At the time of HSCT, 70 patients were in first clinical remission
(CR1), 57 in CR2, and 11 in $CR3. Twenty-one patients had T-lineage disease; 43 patients (31%) had high-
risk cytogenetics of either t(9;22) (n5 33), t(4;11) or t(1,19) abnormalities, with the remainder (69%) having
normal cytogenetics.White blood cell count (WBC)$30 109/L at diagnosis was documented in 33%. Demo-
graphics and disease characteristics were similar in all 4 groups except all UCB recipients were treated since
1996 and received growth factors.Overall survival (OS) at 3 years for theUCB groupwas 66% (95% confidence
interval [CI] 44%-89%) compared to 27% (95%CI 17%-36%) in the MRD group, and only 13% (95%CI 0%-31%)
and14% (95%CI 0%-33%) in theURD:MandURD:MMgroups, respectively. Similarly leukemia free survival (LFS)
at 3 years was better in the UCB group at 61% (95% CI 38%-84%) than 27% (95%CI 18%-36%) in the MRD and
only 13% (95% CI 0%-31%) in the URD:M group and 14% (95%CI 0%-33%) in URD:MM group. Relapse rates at
3 yearswere 5% (95%CI 0%-15%) in theUCBgroup compared to 26% (95%CI 16%-35%) in theMRD, 20% (95%
CI 1%-39%) in theURD:Mgroups, and 0% in theURD:MMgroups. Transplant-relatedmortality (TRM) at 3 years
was the lowest in the UCB group at 34% and higher in the other donor groups: MRD 47%, URD:M 67%, and
URD:MM 86%. In multiple regression analysis, 5 independent risk factors were significantly associated with
poorer OS and LFS: use of URD:MM (relative risk [RR] 2.5, 95% CI, 1.2-5.1, P 5 .01), $CR3 at HSCT (RR
3.5, 95% CI, 1.2-9.6, P 5 .02), WBC$30  109/l (RR 1.9, 95% CI, 1.2-3.0, P 5 .01) at diagnosis, recipient and
donor (R/D) cytomegalovirus (CMV) seropositive (RR 3.8, 95%CI, 2.0-7.4, P\.01), and$2 induction regimens
to achieve initial CR (RR 3.5, 95% CI, 1.2-9.6, P5 .02). Graft-versus-host disease (GVHD) was associated with
improvedLFS (RR0.4, 95%CI, 0.2-0.6, P\.01).When comparedwithURD:M,OSwithUCBwas better (RR0.3,
95% CI, 0.1-0.7, P5 .01), supporting the use of UCB as an alternative stem cell source for adults with ALL.
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6/j.bbmt.2008.09.021treatments has been recently demonstrated to be 39%
[1]. The same study showed the superiority of
hematopoietic stem cell transplantation (HSCT) in
standard risk ALL, and that high-risk patients seemed
to benefit less from this approach because of a higher
nonrelapse mortality rate. High risk features included
age older than 35 years, white blood cell (WBC) count
$30  109/L (T lineage) and $100  109/L (B line-
age), and presence of the Philadelphia chromosome [1].
An HLA matched related donor (MRD) is avail-
able to only 30% of patients. Umbilical cord blood
(UCB) has emerged as an attractive alternative when
anMRD is not available because of the rapidity of pro-
curement and the ability to useHLAmismatched units
with a low incidence and severity of graft-versus-host
Biol Blood Marrow Transplant 14:1394-1400, 2008 1395Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic
Leukemiadisease (GVHD) [2-6]. At our institute, the median
time to obtain an UCB graft is 13.5 days compared
to 50 days for an unrelated donor (URD) graft [7].
UCB has been used successfully in children, but in
adults the main hurdles have been graft failure and
delayed engraftment. As techniques to optimally
select cord blood units to overcome these problems
emerge, the use of UCB transplants in adults has
been increasing [8-12]. Here we report our experience
in adult ALL patients undergoing myeloablative
HSCT and assess the relative impact of donor source
on outcomes.PATIENTS AND METHODS
Patient Characteristics
One hundred thirty-eight consecutive adult
patients with ALLunderwentmyeloablative allogeneic
HSCT at the University of Minnesota between July
1979 and May 2005. Baseline demographic data, dis-
ease characteristics, transplant variables, and outcomes
data were obtained from the University of Minnesota
Blood and Marrow Transplant database that contains
prospectively collected data on all patients transplanted
at our institution. This was supplemented by individual
chart reviews. Treatment protocols were approved by
the local institutional review board, and all patients
gave written informed consent prior to transplant.
The 4 donor groups examined were MRD, matched
unrelated donor (URD:M), mismatched unrelated
donor (URD:MM) and UCB. HLA compatibility was
determined by either serotyping or high- resolution
molecular typing for HLA-A, -B, -C, and -DRB1, de-
pending upon available methods at the time of trans-
plantation. All patients receiving adult donor grafts
before 2003 were HLA matched at -A, -B, and
-DRB1 using serologic techniques. Starting in 2003,
all patients were typed using molecular techniques.
Recipients of MRD and URD grafts were matched at
HLA-A and -B at the antigen level and -DRB1 at the
allele level between 2003 and 2004. After 2004, recipi-
ents of URD grafts were matched at HLA-A, -B, -C,
and -DRB1 at the allele level. URD grafts were HLA
matched at 5-6/6 loci until 2004 and 7-8/8 thereafter.
UCB grafts were matched at least 4 of 6 HLA-A, -B
(antigen level), and -DRB1 (allele level) to the recipient
and in patients receiving 2 UCB units to each other.
Among the 19 UCB recipients, 11 had a 4/6 match
and the rest were 5/6 match. In the URD:MM group
all 14 were a 5/6 match.
Disease status was assessed immediately prior to
transplantation and then at day 28 and 100. Patients
were subsequently evaluated at least every 3 months
in the first year, every 6 months in the second year
and yearly thereafter.Eligibility Criteria
Patients were eligible for transplant if they had
high-risk features in first complete remission (CR1)
or were in $CR2. High-risk features were defined
as: a non-T cell phenotype, abnormal cytogenetics of
t(9,22), t(4,11), or t(1,19), WBC at diagnosis $30 
109/L, extramedullary leukemia, or age $35 years.
To be eligible for a myeloablative MRD trans-
plant, patients had to be #55 years of age and for an
URD transplant #45 years of age. All patients had to
have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0-2 and no major
organ dysfunction. Exclusion criteria included hepatic
or renal insufficiency, active ischemic heart disease, or
left ventricular ejection function \45%, significant
obstructive airway disease or diffusion capacity
\50% of predicted, and active infections including
human immunodeficiency virus.
Selection criteria for our UCB grafts have been
previously published [13-15]. UCB recipients received
either single unit or doubleUCB grafts (2 units admin-
istered sequentially) to optimize cell dose. Cord blood
is considered negative for cytomegalovirus (CMV).
Treatment Plan
The pretransplant conditioning regimen consisted
of cyclophosphamide (60 mg/kg intravenously, days
27 and 26), followed by total body irradiation (TBI)
(165 cGy twice daily on days 24, 23, 22, 21) in the
majority of patients in the MRD group. For the UCB
group the conditioning regimen consisted of Cy/Flu/
TBI (cyclophosphamide—60 mg/kg intravenously on
days 27, 26_; fludarabine (25 mg/m2 intravenously
on days 28, 27, 26); TBI (165 cGy twice daily days
24, 23, 22, 21) in 16 patients (84%) and Cy/TBI in
3 (16%). All URD:M and URD:MM recipients
received TBI plus chemotherapy based conditioning.
After 1992 all patients (n5 79, 57%) received granulo-
cyte-colony stimulating factor (G-CSF) support from
day 0 until the absolute neutrophil count (ANC) was
$2.5  109/L for 2 consecutive days. Transfusion
support was provided with irradiated blood products.
All patients received prophylactic antimicrobials
directed towards bacterial, viral, and fungal pathogens.
Systemic antifungals were given empirically for persis-
tent unexplained fevers. GVHD prophylaxis is as
shown in Table 1. Cyclosporine (CSA) and mycophe-
nolate mofetil (MMF) 6 antithymocyte globulin
(ATG) was used as GVHD prophylaxis for all UCB
recipients. The dose of ATG was 15 mg/kg intrave-
nously every 12 hours for 6 doses from days23 to21.
Statistical Analysis
The primary endpoints for this analysis were OS
and leukemia free survival (LFS). The secondary end-
points were relapse and 3 year transplant-related
Table 1. Patient, Disease, and Transplantation Characteristics
Characteristic MRDn 5 90 (%) UCBn 519 (%) URD:Mn 5 15 (%) URD:MMn 5 14 (%) P
Age (years) 1.0
<35 56 (62) 12 (63) 9 (60) 9 (64)
$35 34 (38) 7 (37) 6 (40) 5 (36)
Median (range) 30 (18-60) 30 (18-45) 32 (20-48) 31 (18-48)
Gender .35
Male 42 (47) 12 (63) 10 (67) 7 (50)
ALL .28
T cell 17 (19) 2 (10) 2 (13) 0
Non-T cell 73 (81) 17 (90) 13 (87) 14 (100)
WBC at diagnosis .11
Unknown 12 (13) 5 (26) 1 (7) 1 (7)
< 30  109/L 52 (58) 9 (47) 8 (53) 4 (29)
$ 30  109/L 26 (29) 5 (26) 6 (40) 9 (64)
High-risk cytogenetics* 23 (26) 6 (32) 7 (47) 7 (50) .15
CNS involvement 13 (14) 1 (5) 2 (13) 2 (14) .76
No. of induction
regimens to achieve CR1
.60
1 82 (91) 17 (89) 15 (100) 12 (86)
2+ 8 (9) 2 (10) 0 2 (14)
Disease at HSCT .27
CR1 48 (53) 6 (32) 7 (47) 9 (64)
CR2 37 (41) 11 (58) 5 (33) 4 (29)
$CR3 5 (6) 2 (10) 3 (20) 1 (7)
Length of CR1 for patients in CR2 at HSCT
(months)
.03
median 22 42 15 33
Time from diagnosis to HSCT (months) .07
Median (range) 7.4 (2-184) 36 (3-123) 10 (3-236) 8.4 (5-58)
Year of HSCT <.01
$1996 31 (34) 19 (100) 7 (47) 7 (50)
Conditioning regimen <.01
Cy/TBI 76 (84) 3 (16) 0 0
Cy/Flu/TBI 0 16 (84) 0 0
Cy/Bu 2 (2) 0 0 0
TBI + cytarabine 6 (7) 0 0 0
TBI + multiple chemo 6 (7) 0 15 (100) 14 (100)
GVHD prophylaxis <.01
MTX/CSA 40 (45) 0 10 (67) 10 (71)
CSA/MMF ± ATG 0 19 (100) 0 0
T cell depletion 22 (24) 0 4 (27) 3 (21)
MTX/ATG 28 (31) 0 0 0
Unknown 0 0 1 (6) 1 (7)
R/D CMV <.01
Positive/positive 30 (33) 0 1 (7) 3 (21)
Positive/negative 27 (30) 9 (47) 4 (26) 3 (21)
Negative/positive 14 (16) 0 1 (7) 4 (29)
Negative/negative 18 (21) 10 (53) 9 (60) 4 (29)
ALL indicates acute lymphocytic leukemia; ATG, antithymocyte globulin; chemo, chemotherapies; CMV, cytomegalovirus; CNS, central nervous system;
CR, complete remission; Cy, cyclophosphamide; CSA, cyclosporine; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; MMF,
mycophenolate mofetil; MTX, methotrexate; MRD, matched related donor; TBI, total-body irradiation; R/D, recipient/donor; UCB, umbilical cord
blood; URD:M, unrelated matched donor; URD:MM, unrelated mismatched donor; WBC, white blood cell count.
*High-risk cytogenetics 5 t(9;22), t(4;11), or t (1;19).
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ning of transplant until relapse or death. Patients were
censored at the date of last follow-up when calculating
OS and LFS. The statistical endpoints of OS and LFS
were estimated by the Kaplan-Meier [16] method with
95% confidence intervals (CI) derived from standard
errors. Comparison of event curves across various
factors was completed by use of the log-rank test
[16]. Cox regression analysis was used to examine the
independent effect of prognostic factors on OS and
LFS [17]. The cumulative incidences of relapse,
TRM, and acute GVHD (aGVHD) were estimated
by treating deaths as competing risks [18]. Patientand transplant characteristics were compared across
donor type subgroups. Statistical comparison of
continuous factors was performed by the Kruskal-
Wallis test [19]. Differences in categoric factors were
tested across subgroups by the use of the chi-square
test or Fisher’s exact test [20].
Patient and disease-related variables considered
were donor type, GVHD prophylaxis, remission status
at transplant, age at transplant, gendermismatch,CMV
serology, leukemia phenotype, cytogenetics, WBC at
diagnosis, central nervous system (CNS) involvement
at diagnosis, time fromdiagnosis to transplant, number
of induction regimens prior to achieving CR, length of
Figure 1. OS (A) and LFS (B) by donor source.
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LeukemiaCR1 (for CR2 patients), year of transplant, and use of
growth factor posttransplant.
RESULTS
Patient Characteristics
Patient, disease, and transplant characteristics
across the 4 donor groups are shown in Table 1. The
median follow-up time in years was MRD-9.3 (range:
1.2-25.1), URD:M-5.0 (range: 4.9-5.0), URD:MM-
4.4 (range: 0.9-25.1). and UCB-2.0 (range: 0.9-5.7).
The source of all URD stem cells was bone mar-
row (BM); 80% of MRD grafts were BM and 20%
peripheral blood stem cells (PBSC) (P 5 .10). There
were no significant differences in recipient and donor
gender mismatch in the 4 groups. The variables that
were different across the groups were year of trans-
plant after 1996, use of growth factor, T cell depletion,
length of CR1, conditioning regimens, and recipient/
donor (R/D) CMV seropositive status. For patients
transplanted in $CR2 the median length of CR1 was
the longest in the UCB group at 42 months. Posttrans-
plant growth factor was received by 100% of the UCB
group, 40 (44%) of the MRD, 12 (80%) of the
URD:M, and 8 (57%) of the URD:MM groups
(P\ .01). None of the UCB recipients had a T cell-
depleted graft. R/D CMV seropositivity was present
in a third of the MRD groups and was less common
in the URD:M and URD:MM groups.
Overall Survival
TheOS at 3 years for all patientswas 28% (95%CI,
20%-36%) andbydonor groupswas:MRD,27% (95%
CI, 17%-36%); URD:M, 13% (95% CI, 0%-31%);
URD:MM, 14% (95% CI, 0%-33%); and UCB, 66%
(95% CI, 44%-89%) (P\ .01) (Figure 1). In multiple
regression analysis, 5 risk factors were independently
significantly associated with poorer OS (Table 2),
including URD:MM, $CR3 at HSCT, WBC $30 
109/L at diagnosis, R/D CMV seropositivity, and $2
induction regimens to achieve initial CR. There was
no impact on OS by year of transplant, use of growth
factor or grade II-IV aGVHD. For patients in CR1,
the 3-year OS by donor group was: MRD, 26% (95%
CI, 14%-39%); URD:M, 29% (95% CI, 0%-63%);
URD:MM, 11% (95% CI, 0%-39%); and UCB, 63%
(95% CI, 14%-89%) (P5 .02). In a pairwise compari-
son of OS between UCB and URD:M, the outcome
was better for UCB (RR 0.3, 95% CI, 0.1-0.7,
P 5 .01). In a pairwise comparison of OS between
UCB and MRD, there was a trend to better outcome
with UCB, although it did not reach statistical
significance (RR 0.4, 95% CI 0.1-1.2, P 5 .10).
LFS
The overall 3-year LFS was 28% (95% CI, 21%-
36%) and by donor groups was: MRD, 27% (95%CI, 18%-36%); URD:M, 13% (95% CI, 0%-31%);
URD:MM, 14% (95% CI, 0%-33%); and UCB,
61% (95% CI, 38%-84%) (P \ .01) (Figure 1). As
with OS, URD:MM, $CR3, at HSCT, WBC $30
 109/L, R/D CMV seropositivity, and $2 induction
regimens to achieve CRwere factors independently as-
sociated with poor LFS (Table 2). In addition, patients
who developed grade II-IV aGVHD had an improved
LFS. For patients in CR1 the LFS by donor group was:
MRD, 26% (95% CI, 14%-38%); URD:M, 29%
(95% CI, 4%-61%); URD:MM, 11% (95% CI, 0%-
39%); and UCB, 44% (95% CI, 0%-88%) (P 5 .02).
Pairwise comparison of LFS between UCB and
URD:MM revealed that the UCB group had signifi-
cantly better LFS (RR 0.2, 95% CI, 0.1-0.9, P 5 .03).Relapse and TRM
The cumulative incidence of relapse at 3 years in
the donor groups were: MRD, 26% (95% CI, 16%-
35%); URD:M, 20% (95% CI, 1%-39%); URD:MM,
0%; and UCB, 5% (95% CI, 0%-15%) (P 5 .08)
(Figure 2). Factors associated independently with
higher risk of relapse were: R/D CMV seropositivity
and $2 induction regimens to achieve CR (Table 3).
The 3-year TRM in the donor groups were: MRD,
44% (95% CI, 34%-55%); URD:M, 53% (95% CI,
27%-80%); URD:MM, 86% (95% CI, 57%-100%);
and UCB, 34% (95% CI, 12%-56%) (P \ .01)
Table 2. Cox Regression Analysis for OS and LFS
Cox regression
analysis for OS
Factor Relative Risk (95% CI) P
Group
MRD* 1.0
UCB 0.5 (0.2-1.3) .14
URD:M 1.6 (0.7-3.3) .23
URD:MM 2.5 (1.2-5.1) .01
Disease Status
at HSCT
CR1 and CR2* 1.0 .02
CR3+ 3.5 (1.2-9.6)
WBC at diagnosis
<30  109/L* 1.0 .01
$30  109/L 1.9 (1.2-3.0)
R/D CMV serostatus
Negative/negative* 1.0
Positive/negative 1.0 (0.5-1.8) .95
Negative/positive 1.2 (0.6-2.7) .50
Positive/positive 3.8 (2.0-7.4) <.01
No. of induction
regimens prior to CR
1* 1.0
$2 3.5 (1.2-9.6) .02
Grade II-IV GVHD
No* 1.0
Yes (time dependent) 0.7 (0.4-1.2) .17
Cox Regression Analysis—Relapse
Factor Relative Risk (95% C.I.) P
Group
RD* 1.0
UCB 0.3 (0.0-2.4) .28
Unrelated (HLA mm) 0.0 (0.0-.) NE
Unrelated (HLA match) 2.3 (0.6-9.5) .25
R/D CMV serostatus
Negative/negative* 1.0
Positive/negative 0.7 (0.2-2.6) .62
Negative/positive 2.7 (0.8-9.9) .13
Positive/positive 8.4 (2.4-28.8) <.01
Number of induction
regimens prior to CR
1* 1.0
2+ 6.6 (1.9-23.1) <.01
Grade II-IV acute GVHD
no* 1.0
yes (time-dependent) 0.6 (0.3-1.4) .24
CMV indicates cytomegalovirus; CR, complete remission; OS, overall
survival; LFS, leukemia-free survival; GVHD, graft-versus-host disease;
MRD, matched related donor; R/D, recipient/donor; UCB, umbilical
cord blood; URD:M, unrelated matched donor; URD:MM, unrelated
mismatched donor; WBC, white blood cell count.
*Reference group.
Figure 2. Relapse by donor source.
Table 3. Cox Regression Analysis—Relapse
Factor Relative Risk (95% C.I.) P
Group
RD* 1.0
UCB 0.3 (0.0-2.4) .28
Unrelated (HLA mm) 0.0 (0.0-.) NE
Unrelated (HLA match) 2.3 (0.6-9.5) .25
R/D CMV serostatus
Negative/negative* 1.0
Positive/negative 0.7 (0.2-2.6) .62
Negative/positive 2.7 (0.8-9.9) .13
Positive/positive 8.4 (2.4-28.8) <.01
Number of induction
regimens prior to CR
1* 1.0
2+ 6.6 (1.9-23.1) <.01
Grade II-IV acute GVHD
no* 1.0
yes (time-dependent) 0.6 (0.3-1.4) .24
CMV indicates cytomegalovirus; CR, complete remission; GVHD, graft-
versus-host disease; R/D, matched related donor; UCB, umbilical cord
blood.
*Reference group.
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by donor group was:MRD, 27% (95%CI, 14%-40%);
URD:M and URD:MM, 0 %; and UCB, 17% (95%
CI, 0%-44%) (P 5 .27). The 1-year TRM among
CR1 patients was: MRD, 40% (95% CI, 26%-56%);
URD:M, 57% (95% CI, 20%-94%); URD:MM,
89% (95% CI, 56%-100%) (P\ .01).
The incidence of grade III-IV aGVHD in the 4
groups (95% CI) were: MRD, 20% (12%-28%);
URD:M, 10% (0%-40%); URD:MM, 7% (0%-
20%); and UCB-32% (11%-52%) (P 5 .64). ChronicGVHD (cGVHD) incidence at 1 year by donor groups
(95% CI) were: MRD, 22% (13%-31%); URD:M,
47% (20%-74%); URD:MM, 21% (2%-40%); and
UCB, 16% (0%-32%) (P 5 .01). The main causes of
death by donor source were relapsed leukemia (MRD
5 35%, URD:M 5 23%, URD:MM and UCB
5 0%), GVHD (MRD 5 23%, URD:M 5 46%,
URD:MM 5 50%, UCB 5 75%), and infection
(MRD 5 30%, URD:M 5 15%, URD:MM 5 17%,
UCB 5 25%). The remainder of the patients in each
group died of other causes.DISCUSSION
It has been shown that MRD HSCT is the treat-
ment of choice in standard risk ALL in CR1 [1].
It has also been demonstrated that outcomes after re-
lapse are extremely poor, and therefore the emphasis
should be on the most effective treatment being deliv-
ered upfront [21]. Because only about 30% of adults
Figure 3. TRM by donor source.
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Leukemiahave an available MRD, we evaluated the safety and
outcomes for unrelated donor sources. Our results
demonstrated favorable outcomes with UCB com-
pared with URD transplantation.
Our 3-year LFS for MRD transplants performed
in CR1 was 26%, which is somewhat lower than
reported by other groups. In the LALA-94 trial of
175 patients transplanted between 1994 and 2002 in
CR1, the 3-year LFS in the MRD group ranged
from 34% to 44% in the various high risk categories
[22]. Kiehl et al. [23] reported a 42% 5-year LFS for
62 patients in CR1 transplanted between 1990 and
2002. In contrast, in the GOELAMS trial of 39 pa-
tients in CR1 transplanted between 1994 and 2002,
the 6-year LFS was 75% [24]. Likewise, the Attal et
al group reported that 43 patients in CR1 following
the Berlin-Frankfurt-Muster (BFM) induction regi-
men had a 3-year LFS of 68% [25]. The differences
in outcomes may be at least partially explained by
variable patient and disease characteristics, induction
regimens, and number of inductions to achieve CR1.
For the URD:M and MM groups our 3-year OS
and LFS were lower than seen for a high-risk popula-
tion in the UKALLXII/ECOG 2993 study [26] . This
was a small series of 33 high-risk adults transplanted
with URD in CR1. The LFS was 56% with a TRM
of 30%, and no deaths were seen after 15 months.
A retrospective study by Weisdorf and colleagues
[27] demonstrated a 5-year LFS of 44% in CR1 and
36% in CR2 with a TRM of 42% and 40%, respec-
tively. In Philadelphia chromosome-positive ALL the
2-year LFS with URD reported in 18 patients was
49% [28]. Recently reported outcomes of URD
HSCT in Philadelphia-negative patients in CR1
showed a 5-year TRM and OS of 42% and 39%,
respectively [29]. In our series the TRM in the
URD:M group was high at 53%, which could partially
explain our lower LFS rates.
Our analysis included patients transplanted from
1979 to 2005. This prolonged period is a limitation
of this study along with the low numbers of patientsin the URD:M, URD:MM, and UCB groups.
Seventy-four (53%) patients were transplanted prior
to 1996, with most being high-risk patients and with
all the UCB transplants occurring after that time.
Overall, half of our patients were transplanted in
$CR2. These factors may have contributed to the
higher TRM seen in the non-UCB groups. The
improvement in induction regimens, supportive care,
management of CMV infections, use of growth factor,
and better HLA match are factors that could account
for the better results seen in the more recent studies.
Some changes could be subtle and difficult to measure.
Our results demonstrated superior OS and LFS for
UCB compared with URD:M transplants. In the study
by Rocha et al. [30], the 2-year LFS was similar in the 2
groups: 34% for the UCB group and 33% for URD:M
(P5 .21), suggesting that UCB transplants had similar
outcomes to matched unrelated transplants [30].
We also noticed an improved LFS with the devel-
opment of grade II-IV aGVHD suggesting a possible
graft-versus-leukemia effect across all donor sources.
Chim et al. [31] analyzed the outcome of 108 patients
with ALL undergoing transplantation and showed
that among other factors, limited aGVHD resulted in
a better LFS. In a 121 high-risk patient population
the occurrence of aGVHDwas 1of 2 prognostic factors
identified for relapse [32].
Our analysis suggests comparable results of UCB
with other donor sources, and supports the continued
exploration of UCB as an alternative stem cell source
for adults with ALL undergoing transplantation. The
observed and potent graft-versus-leukemia effect of
UCB transplants and comparable outcomes need con-
firmation in large prospective trials, yet offer promise
for adults with ALL.
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